[go: up one dir, main page]

CO2018007680A2 - Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo - Google Patents

Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo

Info

Publication number
CO2018007680A2
CO2018007680A2 CONC2018/0007680A CO2018007680A CO2018007680A2 CO 2018007680 A2 CO2018007680 A2 CO 2018007680A2 CO 2018007680 A CO2018007680 A CO 2018007680A CO 2018007680 A2 CO2018007680 A2 CO 2018007680A2
Authority
CO
Colombia
Prior art keywords
glucosidase
acid
pompe
alpha
treatment
Prior art date
Application number
CONC2018/0007680A
Other languages
English (en)
Inventor
Hung V Do
Richie Khanna
Russell Gotschall
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CO2018007680A2 publication Critical patent/CO2018007680A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar la enfermedad de Pompe que incluye la administración de α-glucosidasa ácida humana recombinante que tiene una glucosilación óptima con residuos de manosa-6-fosfato junto con una cantidad de miglustat eficaz para maximizar la captación en tejidos de la α-glucosidasa ácida humana recombinante a la vez que se minimiza la inhibición de la actividad enzimática de la α-glucosidasa ácida humana recombinante.
CONC2018/0007680A 2015-12-30 2018-07-25 Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo CO2018007680A2 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
US15/394,135 US20170189497A1 (en) 2015-12-30 2016-12-29 Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
PCT/US2016/069243 WO2017117407A1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease

Publications (1)

Publication Number Publication Date
CO2018007680A2 true CO2018007680A2 (es) 2018-08-10

Family

ID=57822129

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007680A CO2018007680A2 (es) 2015-12-30 2018-07-25 Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo

Country Status (15)

Country Link
US (4) US20170189497A1 (es)
JP (3) JP2019501178A (es)
KR (3) KR102510941B1 (es)
AU (2) AU2016381832B2 (es)
BR (1) BR112018013151A2 (es)
CA (1) CA3010205A1 (es)
CL (1) CL2018001773A1 (es)
CO (1) CO2018007680A2 (es)
EA (1) EA201891507A1 (es)
IL (3) IL299470A (es)
MX (2) MX2018008185A (es)
MY (1) MY198085A (es)
PH (1) PH12018501313B1 (es)
SG (1) SG11201804965SA (es)
WO (1) WO2017117407A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172924B2 (en) * 2015-03-19 2019-01-08 Translate Bio, Inc. MRNA therapy for pompe disease
BR112018069965A2 (pt) * 2016-03-30 2019-01-29 Amicus Therapeutics Inc formulações compreendendo alfa-glucosidase ácida recombinante
US11944628B2 (en) 2017-05-12 2024-04-02 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
CN119113091A (zh) * 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
MA51796A (fr) 2018-02-07 2020-12-16 Regeneron Pharma Procédés et compositions pour l'administration de protéines thérapeutiques
SG11202011232VA (en) 2018-05-17 2020-12-30 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
CN114341333A (zh) 2019-09-06 2022-04-12 阿米库斯治疗学公司 用于捕获和纯化生物制品的方法
IL305103A (en) * 2021-02-11 2023-10-01 Amicus Therapeutics Inc Recombinant human acid alpha-glucosidase and uses thereof
IL316776A (en) * 2022-05-05 2025-01-01 Amicus Therapeutics Inc Methods of treating Pompe disease

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
DK1030839T3 (da) 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2677343T3 (es) 1998-12-07 2018-08-01 Genzyme Corporation Tratamiento de la enfermedad de Pompe
JP2002536407A (ja) 1999-02-12 2002-10-29 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の治療のための置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の使用
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ATE355075T1 (de) 2000-07-18 2006-03-15 Univ Duke Behandlung der glykogenspeicherkrankheit typ ii
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP1441748A4 (en) 2001-10-16 2007-07-11 Rxkinetix Inc HIGHLY CONCENTRATED PROTEIN FORMULATIONS AND MANUFACTURING METHOD
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
SI2444102T1 (sl) 2003-01-31 2015-08-31 Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) * 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
JP2010509344A (ja) 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
US20100184803A1 (en) 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
WO2009066069A1 (en) 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
AU2009214648B2 (en) 2008-02-12 2014-11-13 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
CA2718182A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
AU2009223125A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for Pompe disease
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en) 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
CN103432566A (zh) 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物
ES2564093T3 (es) 2009-04-09 2016-03-17 Amicus Therapeutics, Inc. Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
US20110070643A1 (en) 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
PE20140617A1 (es) * 2011-04-22 2014-05-28 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
KR102076585B1 (ko) 2011-12-22 2020-02-12 센토제너 아이피 게엠베하 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물
MX349992B (es) 2012-03-07 2017-08-22 Amicus Therapeutics Inc Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
EP4397364A3 (en) 2012-05-03 2024-09-04 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
ES2732308T3 (es) 2013-12-23 2019-11-21 Bcn Peptides Sa Análogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis
TWI529396B (zh) 2014-07-18 2016-04-11 Mpi Corp Probe card and its transfer circuit board and signal feed structure
SG10202003753PA (en) * 2014-09-30 2020-05-28 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates

Also Published As

Publication number Publication date
IL259876A (en) 2018-07-31
KR102510941B1 (ko) 2023-03-20
US10857212B2 (en) 2020-12-08
IL259876B (en) 2021-06-30
PH12018501313B1 (en) 2024-01-26
US20180228877A1 (en) 2018-08-16
US20210268074A1 (en) 2021-09-02
AU2016381832B2 (en) 2024-01-25
US11278601B2 (en) 2022-03-22
CA3010205A1 (en) 2017-07-06
US20220370571A1 (en) 2022-11-24
PH12018501313A1 (en) 2019-02-27
JP7358446B2 (ja) 2023-10-10
JP2019501178A (ja) 2019-01-17
BR112018013151A2 (pt) 2018-12-18
AU2016381832A1 (en) 2018-06-28
KR20180099753A (ko) 2018-09-05
JP2024009829A (ja) 2024-01-23
KR102747683B1 (ko) 2024-12-31
IL299470A (en) 2023-02-01
SG11201804965SA (en) 2018-07-30
IL283837A (en) 2021-07-29
AU2024200071A1 (en) 2024-02-01
IL283837B2 (en) 2023-06-01
KR20250007693A (ko) 2025-01-14
EA201891507A1 (ru) 2018-12-28
MX2018008185A (es) 2018-08-28
US20170189497A1 (en) 2017-07-06
KR20230041833A (ko) 2023-03-24
MY198085A (en) 2023-07-31
MX2022010311A (es) 2022-09-19
CL2018001773A1 (es) 2018-08-24
WO2017117407A1 (en) 2017-07-06
JP2022058423A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
CO2018007680A2 (es) Alfa-glucosidasa con mayor cantidad de ácido para el tratamiento de la enfermedad de pompe campo
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
BR112017023269A2 (pt) métodos para tratamento de câncer
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2019003251A1 (es) Alfa-glucosidasa ácida humana recombinante.
CL2018002768A1 (es) Formulaciones que comprenden alfa-glucosidasa ácida recombinante
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2017001898A (es) Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.
CL2021000033A1 (es) Nuevos compuestos
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
DK4009942T3 (da) Forbindelse til kombinationsbehandling
MX373322B (es) Tratamiento de los síntomas asociados a terapia privación de andrógenos.
MY205171A (en) Methods of treatment of hypertriglyceridemia
CY1124637T1 (el) Αυξημενη οξινη αλφα-γαυκοσιδαση για την θεραπευτικη αγωγη της νοσου ρομρe
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA201491048A1 (ru) Соединения двухцепочечных рнк к casp2 и их применение
AR107277A1 (es) a-GLUCOSIDASA CON MAYOR CANTIDAD DE ÁCIDO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE POMPE
UA106471U (uk) Засіб для лікування дерматологічних захворювань
UA104019U (ru) Способ лечения хронической сердечной недостаточности
UA109840C2 (uk) Спосіб визначення "робочої" площі правого шлуночка серця при синдромі гіпоплазії лівих відділів серця